Clinical Trial Detail

NCT ID NCT03415854
Title Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors HonorHealth Research Institute
Indications

pancreatic ductal adenocarcinoma

Therapies

Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol

Age Groups: adult senior

No variant requirements are available.